Chemotherapy-induced toxic erythema under treatment with pegylated liposomal doxorubicin: No restriction to palms and soles.
Ziemer
Mirjana
M
Goetze
Steven
S
Kaatz
Martin
M
Elsner
Peter
P
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001365:Axilla; D001562:Benzimidazoles / Q000627:therapeutic use; D004121:Dimethyl Sulfoxide / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects*; D004890:Erythema / Q000139:chemically induced* / Q000188:drug therapy; D005260:Female; D005528:Foot; D006225:Hand; D006801:Humans; D008081:Liposomes; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy; D010292:Paresthesia / Q000139:chemically induced* / Q000188:drug therapy*; D011728:Pyridones / Q000627:therapeutic use
C524063:2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one; D000970:Antineoplastic Agents; D001562:Benzimidazoles; D008081:Liposomes; D011728:Pyridones; D004317:Doxorubicin; D004121:Dimethyl Sulfoxide